New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
08:39 EDTCMRXChimerix shares remain undervalued, says Cowen
Cowen believes shares of Chimerix remain undervalued following its dinner management. The firm remains confident its SUPPRESS trial for brincidofovir will succeed in 2015 and expects other opportunities for the drug to materialize in 2014. Shares are Outperform rated with a $27 price target.
News For CMRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
18:41 EDTCMRXChimerix to cease further participation in studies of brincidofovir for Ebola
Chimerix announced that after discussion with the U.S. Food and Drug Administration, the company is ceasing further participation in all current and future clinical studies of brincidofovir for Ebola Virus Disease, including the study announced in December in Liberia sponsored by investigators at the University of Oxford and the supportive Phase 2 study of brincidofovir for EVD, Study 205. The decision to cease further study of brincidofovir in individuals with Ebola Virus Disease does not impact the company's continued focus on advancing brincidofovir in pivotal studies of CMV prevention in recipients of allogeneic hematopoietic transplant and for the treatment of adenovirus infection in immunocompromised patients.
14:05 EDTCMRXPatient at UC Davis Medical center tests negative for Ebola, WSJ reports
Subscribe for More Information
January 29, 2015
13:51 EDTCMRXPotential Ebola patient being treated at UC Davis Medical Center, KCRA says
Subscribe for More Information
January 25, 2015
13:57 EDTCMRXUK nurse make full recovery from Ebola, WSJ says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use